Document:

Exhibit 10.1

 

EXTENSION AGREEMENT

 

THIS EXTENSION AGREEMENT (this “Agreement”) is entered into as of April 12th, 2011, by and between BROTMAN MEDICAL CENTER, INC., a California corporation (“Borrower”) and JHA WEST 16, LLC, a Delaware limited liability company (“Lender”).

 

RECITALS

 

WHEREAS, Borrower and Lender (collectively, the “Parties”) are parties to that certain Loan Agreement, dated as of July 9, 2008 (the “Loan Agreement”);

 

WHEREAS, the Parties have amended the Loan Agreement pursuant to that certain AMENDMENT NO. 1 TO LOAN AGREEMENT dated as of April 14, 2009;

 

WHEREAS, Borrower has executed and delivered to Lender its Promissory Note dated April 14, 2009, in the face amount of Sixteen Million Dollars ($16,000,000);

 

WHEREAS, the Parties have entered into that certain AMENDMENT NO.1 TO PROMISSORY NOTE dated as of February 10, 2010, pursuant to which the Note was amended to provide that at any time following October 14, 2010, and prior to the date which is twenty-four (24) months after the Closing Date, Lender shall have the right to require Borrower to fully repay the Loan Balance, provided that Lender notifies Borrower in writing of its exercise of the Put Right at least one hundred eighty (180) days in advance;

 

WHEREAS, Borrower and Lender have entered into that certain Option Agreement dated as of April 14, 2009, pursuant to which Lender has been given an option to purchase the Property subject to the terms and conditions set forth therein;

 

WHEREAS, Borrower has requested that Lender extend the Maturity Date of the Loan for 75 days (the “Extension”) in order to continue its discussions with respect to modification of the Loan;

 

WHEREAS, Lender has agreed to Borrower’s request for the Extension subject to the terms and conditions hereinafter set forth; and

 

WHEREAS, capitalized terms used, but not otherwise defined herein, shall have the meanings given to such terms in the Loan Agreement, as amended.

 

NOW, THEREFORE, in consideration of the mutual promises herein made, and in consideration of the representations, warranties, and covenants herein contained, the Parties hereby agree as follows:

 

AGREEMENT

 

1.             The term Maturity Date as used in the Loan Agreement is hereby amended and restated as follows:

 

 

“Maturity Date:  The earlier to occur of (i) June 28, 2011, (ii) one hundred eighty (180) days after Lender’s exercise of the Put Right, and (iii) if Lender, in its capacity as the “Buyer” under the Option Agreement, exercises the Option during the Option Period (as such period may be extended pursuant to the term thereof), the date of the closing of the transaction contemplated by the Option Agreement.”

 

2.             Option Period.  In light of the extension of the Maturity Date, the parties acknowledge that the Option Period is also extended to June 28, 2012, rather than one year from the original Maturity Date.

 

3.             Memorandum.  The Parties shall execute a memorandum of this Agreement (the “Memorandum”) which is to be in recordable form and recorded in the Official Records of Los Angeles County, California.  At the request of Lender, the title company which issued the title policy insuring the validity and priority of the Deed of Trust securing the Note (the “Title Policy”) shall issue an endorsement to the Title Policy (the “Endorsement”) insuring that the Deed of Trust continues to be subject to no exceptions to title not approved by Lender as set forth in the Title Policy.  The cost of recording the Memorandum and the charge for issuing the Endorsement shall be borne by Borrower.

 

4.             Choice of Law.  This Agreement shall be governed by and construed in accordance with the laws of the State of California, without giving effect to conflicts of law principles.

 

5.             Miscellaneous.  All terms and provisions of the Loan Documents not modified hereby shall remain unmodified and in full force and effect.

 

6.             Integration; Interpretation.  The Loan Documents, including this Agreement, contain or expressly incorporate by reference the entire agreement of the Parties with respect to the matters contemplated herein and supersede all prior negotiations. The Loan Documents shall not be modified except by written instrument executed by all Parties.

 

7.             Execution in Counterpart.  This Agreement, and other Loan Documents which expressly so provide, may be executed in any number of counterparts, each of which when executed and delivered will be deemed to be an original and all of which, taken together, will be deemed to be one and the same instrument.

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective officers thereunto duly authorized, as of the date first above written.

 

	
 
    	
 
    	
“BORROWER”
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
BROTMAN   MEDIAL CENTER, INC.,
    
	
 
    	
 
    	
a   California corporation
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Von Crockett
    
	
 
    	
 
    	
 
    	
Name:   
    	
Von   Crockett
    
	
 
    	
 
    	
 
    	
Title:   
    	
Chief   Executive Officer
    

 

2

 

	
 
    	
 
    	
“LENDER”
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
JHA   WEST 16, LLC,
    
	
 
    	
 
    	
a   Delaware limited liability company
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
JHA   Geriatric Services, Inc., a California corporation
    
	
 
    	
 
    	
Its:
    	
Sole   Member
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   M.M. Forrest
    
	
 
    	
 
    	
 
    	
Name:
    	
M.M.   Forrest
    
	
 
    	
 
    	
 
    	
Title:
    	
Chief   Executive Officer
    

 

3Exhibit 10.2

 

THIRD AMENDMENT TO CREDIT AGREEMENT AND WAIVER

 

THIS THIRD AMENDMENT TO CREDIT AGREEMENT AND WAIVER (this “Amendment”), dated as of April 29, 2011, is made by and between BROTMAN MEDICAL CENTER, INC., a California corporation, as borrower (“Borrower”) and GEMINO HEALTHCARE FINANCE, LLC, a Delaware limited liability company, as lender (“Lender”).

 

BACKGROUND STATEMENT

 

A.                                   Borrower and Lender are parties to a Credit Agreement, dated as of April 14, 2009 (as amended by that certain First Amendment to Credit Agreement and Waiver, dated as of December 11, 2009, and that certain Second Amendment to Credit Agreement, dated as of February 17, 2010, and as further amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”). Capitalized terms used herein without definition shall have the meanings given to them in the Credit Agreement.

 

B.                                     Borrower has requested that Lender (i) waive a certain Event of Default pursuant to Section 8.01(b) of the Credit Agreement and (ii) agree to make certain revisions to the Credit Agreement. Lender has agreed to make the following amendments to the Credit Agreement and provide the following waiver, subject to the terms and conditions set forth herein.

 

STATEMENT OF AGREEMENT

 

The parties hereto, in consideration of the mutual covenants and agreements set forth herein, agree as follows:

 

ARTICLE I

 

AMENDMENTS

 

1.1                                 Amendment to Section 6.06(b). The Credit Agreement is hereby amended by deleting Section 6.06(b) in its entirety and replacing it with the following:

 

“(b)                           Fixed Charge Coverage Ratio. Borrower shall maintain a Fixed Charge Coverage Ratio measured quarterly at the end of each fiscal quarter of not less than 1.0:1.0 for the fiscal quarter ending March 31, 2011 and each fiscal quarter thereafter.

 

The Fixed Charge Coverage Ratio shall be calculated on a rolling four quarter basis ending with the quarter being measured, provided, however, that for the fiscal quarters ending March 31, 2011, June 30, 2011, and September 30, 2011, the Fixed Charge Coverage Ratio shall be calculated on a cumulative annualized basis.  The reporting and calculation of the Fixed Charge Coverage Ratio shall commence for the fiscal quarter ending March 31, 2011.”

 

1.2                                 Amendment to Definition of “Fixed Charge Coverage Ratio”.  The definition of “Fixed Charge Coverage Ratio” in Annex I of the Credit Agreement is hereby amended by deleting it in its entirety and replacing it with the following:

 

 

“Fixed Charge Coverage Ratio” means the ratio of (a) EBITDAC, less any revenue and expenses (not including legal fees) incurred due to AB 1383, to (b) the sum of (i) the current portion of any long-term Indebtedness (provided, that any indebtedness under the JHA Loans shall not be considered “current” so long as (A) the Borrower is in full compliance with the terms of the JHA Loans, (B) the Borrower has not received any notices of default or similar notices by JHA or its assignees, (C) JHA or its assigns have not terminated the JHA Loans or exercised any remedies against the Borrower, and (D) JHA or its assigns have not exercised, or provided notice of their exercise, of any put right, including, without limitation, the Put Right as defined in the JHA Loan Documents)(further  provided, that any portion of the indebtedness related to the AB 1383 liability shall not be considered “current” to the extent there exists at all times a written, enforceable commitment from Shareholders to immediately fund such liability to the Borrower when it is either paid by the Borrower or withheld from Borrower’s Medi-Cal remittances), plus (ii) the current portion of lease payments under capitalized leases, plus (iii) cash interest paid, plus (iv) income taxes paid, plus (v) Unfunded Capital Expenditures, plus (vi) any Distributions paid in cash, plus (vii) any consulting fees (including without limitation the Prospect Consulting Fee) paid, plus (viii) current portion of any amount due to CMS under any extended repayment plan in connection with any CMS Claim, in accordance with generally accepted accounting principles consistently applied, calculated on a rolling four quarter basis ending with the quarter being measured, provided, however, that for the fiscal quarters ending March 31, 2011, June 30, 2011, and September 30, 2011, the Fixed Charge Coverage Ratio shall be calculated on a cumulative annualized basis, though the cash payments of (a)(ii) and (b)(ix) above shall not be annualized.”

 

1.3                                 New Definition of “Unfunded Capital Expenditure”.  The following new definition of Unfunded Capital Expenditure shall be added to Annex I:

 

“Unfunded Capital Expenditure” means expenditures by Borrowers for the acquisition of capital equipment, improvements or other capital assets that are not funded by the incurrence of any Indebtedness or cash received from Borrower’s $3.75MM Rights Offering in November of 2010.”

 

ARTICLE II

 

WAIVER

 

2.1                                 Financial Covenants.                                Lender hereby waives the Event of Default pursuant to Section 8.01(b) of the Credit Agreement resulting from Borrower’s failure to comply with Section 6.06(b) of the Credit Agreement with respect to the testing period ending December 31, 2010.

 

2

 

ARTICLE III

 

REPRESENTATIONS AND WARRANTIES

 

Borrower hereby represents and warrants as follows:

 

3.1                                 Representations and Warranties. After giving effect to this Amendment, each of the representations and warranties of Borrower contained in the Credit Agreement and in the other Loan Documents is true and correct on and as of the date hereof with the same effect as if made on and as of the date hereof (except to the extent any such representation or warranty is expressly stated to have been made as of a specific date, in which case such representation or warranty is true and correct as of such date).

 

3.2                                 No Default. After giving effect to this Amendment, no Event of Default or Unmatured Event of Default has occurred and is continuing.

 

3.3                                 Enforceability. This Amendment has been duly executed and delivered by Borrower and constitutes Borrower’s legal, valid and binding obligation, enforceable in accordance with its terms, except as such enforceability may be limited (a) by general principles of equity and conflicts of laws or (b) by bankruptcy, reorganization, insolvency, moratorium or other laws of general application relating to or affecting the enforcement of Lender’s rights.

 

3.4                                 No Conflicts. No consent, approval, authorization or order of, or filing, registration or qualification with, any court or governmental authority or third party is required in connection with the execution, delivery or performance by Borrower of this Amendment.

 

3.5                                 Obligations. The execution and delivery of this Amendment does not diminish or reduce Borrower’s obligations under the Loan Documents, except as modified by this Amendment.

 

3.6                                 No Claims. Borrower has no claims, counterclaims, offsets or defenses to the Loan Documents or the performance of its obligations thereunder, or if Borrower has any such claims, counterclaims, offsets, or defenses to the Loan Documents or any transaction related to the Loan Documents, the same are hereby waived, relinquished and released in consideration of Lender’s execution and delivery of this Amendment.

 

ARTICLE IV

 

CONDITIONS TO EFFECTIVENESS

 

The effectiveness of the amendments to the Credit Agreement and of the waiver set forth in this Amendment is subject to the satisfaction of the following conditions:

 

4.1                                 Executed Amendment and Other Documents. This Amendment and any other documents required by Lender in its sole discretion shall have been duly executed and delivered by Borrower in form and substance satisfactory to Lender in its sole discretion.

 

4.2                                 Fees.  Prior to closing of this Amendment, Borrower shall have paid to Lender (i) all Expenses (including without limitation the reasonable fees and expenses of counsel to Lender) associated with this Amendment and (ii) Seventeen Thousand Five Hundred Dollars ($17,500) to Lender as a waiver and amendment fee.

 

3

 

4.3                                 No Material Adverse Change. No Material Adverse Effect has occurred and is continuing, and no Borrower knows of any event, condition or state of facts that could reasonably be expected to have a Material Adverse Effect.

 

ARTICLE V

 

MISCELLANEOUS

 

5.1                                 Effect of Amendment. From and after the Effective Date (as defined below), all references to the Credit Agreement set forth in any other Loan Document or other agreement or instrument shall, unless otherwise specifically provided, be references to the Credit Agreement as amended by this Amendment and as may be further amended, modified, restated or supplemented from time to time. This Amendment is limited as specified and shall not constitute or be deemed to constitute an amendment, modification or waiver of any provision of the Credit Agreement or of any other Loan Document except as expressly set forth herein. Except as expressly amended hereby, the Credit Agreement shall remain in full force and effect in accordance with its terms.

 

5.2                                 Governing Law. This Amendment shall be governed by and construed and enforced in accordance with the laws of the Commonwealth of Pennsylvania (without regard to the conflicts of law provisions thereof).

 

5.3                                 Expenses. Borrower agrees to pay upon demand all out-of-pocket costs and expenses of Lender (including, without limitation, the reasonable fees and expenses of counsel to Lender) in connection with the preparation, negotiation, execution and delivery of this Amendment.

 

5.4                                 Severability. To the extent any provision of this Amendment is prohibited by or invalid under the applicable law of any jurisdiction, such provision shall be ineffective only to the extent of such prohibition or invalidity and only in any such jurisdiction, without prohibiting or invalidating such provision in any other jurisdiction or the remaining provisions of this Amendment in any jurisdiction.

 

5.5                                 Successors and Assigns.  This Amendment shall be binding upon, inure to the benefit of and be enforceable by the respective successors and assigns of the parties hereto.

 

5.6                                 Construction. The headings of the various sections and subsections of this Amendment have been inserted for convenience only and shall not in any way affect the meaning or construction of any of the provisions hereof.

 

5.7                                 Counterparts; Effectiveness. This Amendment may be executed in any number of counterparts and by different parties hereto on separate counterparts, each of which when so executed and delivered shall be an original, but all of which shall together constitute one and the same instrument. This Amendment shall become effective upon the execution and delivery of a counterpart hereof by Borrower and Lender and the satisfaction of the conditions set forth in Article III hereof (such date, the “Effective Date”).  Signatures of the parties to this Amendment

 

4

 

transmitted by facsimile or via other electronic format shall be deemed to be their original signatures for all purposes.

 

[Signatures on following page.]

 

5

 

IN WITNESS WHEREOF, this Amendment has been duly executed as of the day and year first above written.

 

	
BORROWER:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Address for notices to   Borrower:
    	
BROTMAN MEDICAL CENTER, INC.
    
	
 
    	
 
    	
 
    
	
Brotman Medical Center, Inc.
    	
 
    	
 
    
	
3828 Delmas Terrace
    	
 
    	
 
    
	
Culver City, CA 90231
    	
 
    	
 
    
	
Attn: Von Crockett, Chief Executive Officer
    	
By:
    	
/s/   Von Crockett
    
	
Fax: (310) 202-4125
    	
Name:
    	
Von   Crockett
    
	
 
    	
Title:
    	
Chief   Executive Officer
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
LENDER:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Address for notices to   Lender:
    	
GEMINO HEALTHCARE FINANCE, LLC
    
	
 
    	
 
    	
 
    
	
Gemino Healthcare Finance,   LLC
    	
 
    	
 
    
	
1 International Plaza, Suite 220
    	
By:
    	
/s/   Stacy L. Allen
    
	
Philadelphia, PA 19113
    	
Name:
    	
Stacy   L. Allen
    
	
Attn: Miriam Gallagher
    	
Title:
    	
Vice   President
    
	
Fax: (610) 870-5401
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
With a copy to (which shall not constitute   notice):
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Waller Lansden   Dortch & Davis, LLP
    	
 
    	
 
    
	
511 Union Street, Suite 2700
    	
 
    	
 
    
	
Nashville City Center
    	
 
    	
 
    
	
Nashville, TN 37219
    	
 
    	
 
    
	
Attn: Robert L. Harris
    	
 
    	
 
    
	
Fax: (615) 244-6804

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}]]